Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP forum goes gratis

This article was originally published in The Tan Sheet

Executive Summary

The Pharmacopeial Forum becomes a free online resource starting in January, the U.S. Pharmacopeia says Sept. 8, allowing "greater participation in the standards-setting process for drugs, excipients and dietary supplements." PF is the nonprofit group's journal for public comment, giving manufacturers, regulators and other stakeholders a chance to provide feedback on proposed standards before they become official in USP's National Formulary. The May-June issue of PF sought comments on standards for bacopa monnieri, garcinia gummi-gutta and other Indian botanicals used in supplements and traditional medicines (1"The Tan Sheet" May 10, 2010, In Brief)

You may also be interested in...



USP standardizes Indian botanicals

The U.S. and Indian pharmacopeias jointly propose standards for the identity, strength, quality and purity of four botanical articles in multiple forms used in U.S. dietary supplements and Indian traditional medicines. Monographs for the botanicals bacopa monnieri, garcinia gummi-gutta, garcinia indica and plectranthus barbatus are in the May-June issue of Pharmacopeial Forum, USP said May 5. The Rockville, Md.-based organization seeks comments on the standards before they are finalized. USP will publish official monograph standards for the botanicals ashwagandha root, andrograpahis aerial parts and boswellia serrata in February 2011, USP said

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel